Table 2:
Patients on PancSeq protocol who underwent treatment with experimental agents. Bolded genes indicate those genetic alterations that guided choice of experimental therapy. A “g” preceding the gene name refers to “germline.” GA, gemcitabine plus albumin-bound paclitaxel; FOLFIRINOX, 5-FU/Leucovorin/Irinotecan/Oxaliplatin; FOLFOX, 5-FU, Leucovorin, Oxaliplatin; mAb, monoclonal antibody; Nal-Iri, nanoliposomal irinotecan; Cape, capecitabine; CT, clinical trial; OL, off-label; SP-IND, single-patient investigational new drug application.
| Identifier | Gender | Age (yrs) | Stage | Pre-Biopsy Treatments for Advanced Disease | Genomic Features | Post-Biopsy Treatments |
|---|---|---|---|---|---|---|
| 0400068_T1 | M | 44 | Metastatic | No prior chemotherapy | BRCA2, KRAS | FOLFIRINOX -- PARP inhibitor (OL) |
| 0400075_T1 | F | 58 | Metastatic | No prior chemotherapy | CHEK2, KRAS, gBRCA1 | FOLFIRINOX -- PARP inhibitor vs. placebo (CT) |
| 0400078_T1 | F | 39 | Metastatic | GA/JAK inhibitor (CT), FOLFIRINOX | KRAS, CDKN2A, gBRCA2 | UBA1 inhibitor (CT) -- PARP inhibitor (OL) |
| 0400096_T1 | M | 57 | Metastatic | No prior chemotherapy | KRAS, CDKN2A | FOLFIRINOX -- GA/Anti-MUC5AC mAb (CT) |
| 0400097_T1 | M | 48 | Metastatic | No prior chemotherapy | KRAS | FOLFIRINOX -- GA -- CHK1/2 inhibitor (CT) |
| 0400117_T2 | F | 65 | Metastatic | FOLFIRINOX, GA | KRAS, CDKN2A | PI3K/mTOR inhibitor/CDK4/6 inhibitor (CT) |
| 0400127_T1 | F | 60 | Metastatic | No prior chemotherapy | KRAS, CDKN2A | FOLFIRINOX -- GA -- CDK4/6 inhibitor/MEK1/2 inhibitor (CT) |
| 0400151_T2 | F | 61 | Metastatic | FOLFIRINOX, GA | KRAS, CDKN2A | CDK2/5/9 inhibitor (CT) |
| 0400165_T1 | F | 73 | Metastatic | FOLFIRINOX | ERCC2, KRAS | GA -- Prostaglandin E2 receptor EP4 antagonist (CT) |
| 0400172_T1 | M | 58 | Metastatic | No prior chemotherapy | BRAF, CDKN2A | FOLFIRINOX -- MEK1/2 inhibitor (OL) -- GA -- ERK1/2 inhibitor (SP-IND) |
| 0400174_T1 | M | 77 | Metastatic | No prior chemotherapy | ATM (biallelic), KRAS, CDKN2A | GA -- 5FU/LV/Nal-Iri -- PARP inhibitor (OL) |
| 0400177_T1 | F | 64 | Metastatic | FOLFOX, 5FU/LV/Nal-Iri, GA | KRAS, NBN, FANCM | PARP inhibitor/CDK1/2/5/9 inhibitor (CT) |
| 0400197_T1 | F | 65 | Metastatic | FOLFIRINOX, GA | BRAF, FGFR1 (amplification) | MEK1/2 inhibitor (OL) -- ERK1/2 inhibitor (SP-IND) |
| 0400202_T1 | M | 83 | Metastatic | ROS1 inhibitor (CT) | CDKN2A, ROS1 (translocation) | ROS1 inhibitor (OL) -- ROS1 inhibtor (OL) |
| 0400242_T1 | F | 63 | Metastatic | No prior chemotherapy | KRAS, CDKN2A, gBRCA1 | FOLFIRINOX -- PARP inhibitor vs. placebo (CT) |
| 0400245_T1 | M | 57 | Metastatic | No prior chemotherapy | KRAS | FOLFIRINOX -- anti-PD-1 mAb/CXCR4 antagonist (CT) -- GA |
| 0400270_T1 | F | 66 | Metastatic | GA, Cape, 5FU/LV/Nal-Iri, FOLFOX | KRAS | anti-PD-1 mAb/anti-GITR mAB agonist (CT) |